US2023322774A1PendingUtilityA1
Dimethyl amino azetidine amides as jak inhibitors
Assignee: THERAVANCE BIOPHARMA R&D IP LLCPriority: Sep 4, 2018Filed: Mar 9, 2023Published: Oct 12, 2023
Est. expirySep 4, 2038(~12.1 yrs left)· nominal 20-yr term from priority
C07D 471/04A61K 31/437A61P 11/00A61P 37/06
79
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides compounds of formula (I):where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
Claims
exact text as granted — not AI-modified1 .- 23 . (canceled)
24 . A pharmaceutical composition comprising a compound of formula 1:
or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.
25 . The pharmaceutical composition of claim 24 , wherein the pharmaceutical composition is administered by inhalation.
26 . The pharmaceutical composition of claim 24 , wherein the pharmaceutical composition is administered by inhalation using a nebulizer inhaler.
27 . A pharmaceutical composition comprising a compound of formula 1:
and a pharmaceutically-acceptable carrier.
28 . The pharmaceutical composition of claim 27 , wherein the pharmaceutical composition is administered by inhalation.
29 . The pharmaceutical composition of claim 27 , wherein the pharmaceutical composition is administered by inhalation using a nebulizer inhaler.Join the waitlist — get patent alerts
Track US2023322774A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.